Clinical Trials Logo

Hepatobiliary Diseases clinical trials

View clinical trials related to Hepatobiliary Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT05264688 Recruiting - Clinical trials for Hepatobiliary Diseases

The Function of PET Molecular Imaging Targeting Fibroblast Activation Protein in the Hepatobiliary Malignancies

Start date: January 20, 2022
Phase:
Study type: Observational

Patients with high clinical suspicion of hepatobiliary malignancies should undergo PET/CT examination with two imaging agents, 68Ga-FAPI (fibroblast activation protein inhibitor) and 18F-FDG within one week, and collect tumor tissue. Finally, the PET/CT results were compared with the pathology report to evaluate the role of 68Ga-FAPI PET/CT imaging in the diagnosis of hepatobiliary malignancies

NCT ID: NCT01200082 Terminated - Clinical trials for Hepatobiliary Diseases

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

Start date: November 2011
Phase:
Study type: Observational

The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury would provide the foundation for a specific and non-invasive tool to evaluate disease prognosis, determine patients with higher risk of developing end-stage liver diseases, and determine patients with higher risk of recurrence of hepatobiliary complications after liver transplant. Patients on the liver transplant list are continuously monitored during their hospitalization and are scheduled for follow-up visits for 12 months after their release post-surgery. Disease progression will be evaluated by monitoring MELD scores, survival, incidence of liver transplant, and incidence of complications related to hepatobiliary conditions such as fluid retention, GI bleeding, encephalopathy, and biliary stricture complications.